You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Prenetics, which operates in 10 countries, will use the funding for R&D and plans to launch a rapid coronavirus nucleic acid test in Q4.
Researchers profiled T cells in the cerebrospinal fluid of healthy individuals and multiple sclerosis patients using single-cell RNA-seq and T cell receptor sequencing.
News items for the week of Sept. 14, 2020.
The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.
Visby's test is a fully integrated PCR device that detects SARS-CoV-2 RNA, while SNIBE's test comprises assays for two different antibodies against the virus.
The University of Michigan spinout will use the funds to develop its InheRET platform, increase integration with EHRs, as well as increase its workforce and userbase.
The company said it will use the capital to accelerate the growth and development of its infrastructure and CRISPR-based chips.
In 2018 Qiagen purchased a 19.9 percent stake in Ann Arbor, Michigan-based NeuMoDx along with the right to acquire the remaining shares.
The Manhattan-based lab will scale its capacity to process 20,000 tests per day by November and provide results dedicated to the city.
Participants were especially reluctant to donate their de-identified DNA and medical data to for-profit companies or to multiple entities.
Single-cell RNA sequencing on adrenal gland samples with or without neuroblastoma helped track down key malignant subtypes and tumor features, providing prognostic clues.
Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.
The firms aim to combine their respective products and expertise to provide comprehensive R&D solutions for drug development in oncology.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.
The company's revenues for the first half of the year were up over 900 percent on strong sales of its PCR-based SARS-CoV-2 test and related products.
An expanded agreement grants Qiagen a non-exclusive development license to Bio-Techne's exosome technology for the development of companion diagnostic products.
The firm's assay is also CE marked for use with nasal swabs, nasopharyngeal swabs, nasal wash and aspirates, and bronchoalveolar lavages.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
Researchers studied the genetic structure of Viking Age Scandinavian populations, along with migrations and the adoption of Viking culture by non-Scandinavians.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
Researchers characterized more than 100 ancient equid samples stretching over some 9,000 years, spanning the early Neolithic Age to the Iron Age.
The company, which originally announced plans for a possible spin off in June, will hold a shareholder meeting to vote on the details in October.
Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.